

EP 0 271 709 (1)
C07D295/18B1B-C07C101/447-

ation number:

0 271 709
A1

-2- BASIC DOC.-

C07C101/447

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 87116513.0

(51) Int. Cl. 4: C07C 101/447, C07D 295/08,
A61K 31/195, A61K 31/40,
A61K 31/445

(22) Date of filing: 09.11.87

(30) Priority: 13.11.86 IT 2232086

(43) Date of publication of application:
22.06.88 Bulletin 88/25

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: ALTERGON S.A.
Via Dogana Vecchia 2
CH-6903 Lugano(CH)

(72) Inventor: Ziggliotti, Antonio
Vezia Ticino(CH)

(74) Representative: Gervasi, Gemma, Dr.
NOTARBARTOLO & GERVASI Srl 33, Viale
Bianca Maria
I-21100 Milano(IT)

(54) Salt of diclofenac with a cyclic organic base and pharmaceutical compositions which contain it.

(57) The salt of diclofenac with a cyclic organic base is prepared by dissolving diclofenac in a suitable organic solvent, adding said cyclic organic base, reacting the two components together, removing the solvent and crystallising the product obtained.

Said salt is water soluble to an extent from 20% w/v to an extent exceeding 50% w/v, and is used to prepare pharmaceutical compositions preferably in granular form for use by dissolving in water for oral administration.

EP 0 271 709 A1


SALT OF DICLOFENAC WITH A CYCLIC ORGANIC BASE, AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN IT

This invention relates to the salt of diclofenac with a cyclic organic base and to pharmaceutical compositions which contain it.

More particularly, the invention relates to the salt of diclofenac with a cyclic organic base in the various pharmaceutical forms, and preferably in granular form for use in extemporaneous solutions for oral administration.

Diclofenac (2-[2,6-dichlorophenyl]-amino]benzeneacetic acid) is an anti-inflammatory medicament which has been known for a considerable time and which together with numerous other compounds falls under the general formula of USA patent 3,558,690.

One of the characteristics of these compounds is that they cyclize in an acid environment to give the corresponding indolinones. In order to obtain stabilisation of the open form, they are salified with non-toxic organic or inorganic bases as described for example in the aforesaid patent. However, in this patent no information is given regarding the solubility of said salts in water, and notwithstanding the fact that several years have passed since the teachings of the said patent were made available, no aqueous pharmaceutical composition of diclofenac has been marketed. We have now found that it is possible to obtain a highly watersoluble diclofenac salt by salifying diclofenac with a cyclic organic base having the general formula (I)



in which X is a group of the formula $(\text{CH}_2)_m$, in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group $\text{C}_1\text{--C}_4$, and n is 2 or 3. This is very surprising in the light of the fact that USA patent 3,558,690 comprises salts of diclofenac with bases such as 2-amino-ethanol and pyrrolidine which are very close to the bases of the formula (I) from a structural viewpoint, whereas these salts are practically insoluble in water.

In contrast to the tablet form currently used for oral administration one particular unforeseeable advantage of the salt of diclofenac with a base of formula (I) is that when prepared in granular form and stored in water-impermeable sachets, it enables extemporaneous aqueous solutions to be prepared which while totally maintaining their activity level do not give rise to gastrolesion.

The enormous advantage of such a behaviour which obviates any risk to the patient ingesting the medicament is an obvious considerable merit in terms of its pharmaceutical application.

The salt of diclofenac with a base of formula (I) therefore constitutes a subject of the present invention, a further subject of the invention being pharmaceutical compositions containing a therapeutically useful dosage of said salt.

The process for preparing this salt is extremely simple from an industrial viewpoint, it being characterised by dissolving diclofenac in a suitable organic solvent, adding a base of formula (I), reacting said compounds together at ambient temperature, removing the solvent and crystallising the product obtained.

Suitable organic solvents for dissolving diclofenac are acetone, ethanol and chloroform. The base is used in equimolar quantity or in slight excess with respect to the diclofenac. The reaction is conducted at ambient temperature under agitation for a time of between 0,5 and 3 hours. The solvent is removed by distillation under vacuum at a temperature of between 35 and 45°C. The salt is crystallised by treating the distillation residue with hexane or petroleum ether under energetic agitation.

The unrefined salt obtained is redissolved in acetone and recrystallised from hexane or petroleum ether.

The solubility characteristics of the salt of diclofenac with hydroxyethylpyrrolidine (ID) and with hydroxyethylpiperidine (IP) compared with the salts of diclofenac with sodium (SD), with pyrrolidine (PD) and

with 2-aminoethanol (AD) are given in the following table.

Compound	Solubility (% w/v)	Solution pH	Commencement of precipitation 24 h
ID	> 50	7.5	
IP	>20	..	
SD	1.36	7.6	
PD	practically insoluble		
AD	practically insoluble		

The salt of diclofenac with a base of formula (I) also has high shelf life. The pharmaceutical compositions according to the present invention contain a therapeutically active quantity of the salt of diclofenac with a base of formula (I) together with pharmaceutically acceptable liquid or solid excipients of organic or inorganic type, and can be administered orally. Preferably, said compositions contain an active ingredient quantity corresponding to 10-200 mg of diclofenac per unit dosage.

Examples of preferred pharmaceutical forms are granular forms packaged in sachets of water-impermeable material, and are dissolved in a little water to form solutions for oral administration.

In addition to the excipients, said compositions can contain preservatives, stabilisers, wetting agents, emulsifiers, osmotic pressure regulating salts, buffers, dyes, sweeteners and flavourings. They are prepared by known methods and can contain other therapeutic agents.

The following examples are described by way of non-limiting illustration of the present invention.

EXAMPLE 1

Preparation of the salt of diclofenac with hydroxyethylpyrrolidine

14.75 g (49.8 mmoles) of 2-[(2,6-dichlorophenyl)-amino]benzeneacetic acid (diclofenac) were dissolved in acetone (50 ml), and 5.75 g (49.9 mmoles) of freshly distilled hydroxyethylpyrrolidine were added to the solution obtained.

After keeping the solution under agitation for one hour at ambient temperature, the solvent was removed under vacuum at 40°C.

The oily residue was treated with hexane (100 ml) and the obtained mixture kept under energetic agitation until the oil was transformed into a crystalline solid, which was separated by filtration and dried. 17 g of product were obtained having an M.P. of 57-58°C (yield 83% of theoretical).

The unrefined product obtained in this manner was dissolved in acetone (50 ml), decolorised with animal charcoal and filtered. The solution was evaporated under vacuum, and the residue treated with hexane as described heretofore. The salt of diclofenac with hydroxyethylpyrrolidine was obtained in its pure state, with an M.P. of 97.5-100°C.

EXAMPLE 2

Preparation of the salt of Diclofenac with 1-(2-hydroxyethyl)-piperidine

A solution of 8.9 g of 2-[2,6-dichloro-phenyl]-amino]-phenylacetic acid in 220 ml of ethyl acetate is treated with a solution of 3.88 g of 1-(2-hydroxyethyl)-piperidine in 20 ml ethyl acetate while stirring.

After 30 minutes the clear solution is concentrated under reduced pressure to a volume of 100 ml and diluted with 100 ml diethyl ether. The crystalline 1-(2-hydroxyethyl)-piperidine salt of 2-[(2,6-dichlorophenyl)-amino]-phenylacetic acid precipitates and is filtered off. M.P. 109-111°; solubility in water: 20% w/v.

EXAMPLE 3Preparation of a granulate containing the salt of diclofenac with hydroxyethylpyrrolidine

5 A granulate was prepared having the following composition:

Salt of diclofenac with hydroxyethylpyrrolidine 70 mg

Sorbitol 1798 mg

Aspartame 50 mg

Polyethyleneglycol 6000 150 mg

10 E 124 1 mg

E 110 HC 1 mg

Flavouring 130 mg

70 g of the salt of diclofenac with hydroxyethylpyrrolidine, 1.798 Kg of sorbitol and 50 g of aspartame were mixed together in a steel cube mixer for 20 minutes.

15 150 g of polyethyleneglycol 6000, 1 g of E 124 and 1 g of E 110 HC were dissolved in 250 ml of boiling water under agitation

The solid mixture and solution prepared in this manner were mixed together in a fluidised bed granulator using 100 ml of mixing water. The granulate obtained in this manner was sieved through an oscillating screen with a mesh size of 1 mm.


20 130 g of flavouring was sieved separately with the same screen, and was mixed with the said granulate in a cube mixer for 20 minutes.

The granulate obtained in this manner was dispensed into sachets of water-impermeable material, dispensing 2,2 g of granulate into each sachet.

25 At the moment of use, the contents of each sachet were easily dissolved in a little water to form a drinkable solution which in terms of acid contains 50 mg of diclofenac.


Claims

30 1. The salt of diclofenac (2-[2,6-dichlorophenyl]-amino)-benzeneacetic acid) with a cyclic organic base having the general formula (I)



40 in which X is a group of the formula (CH₂)_m, in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group C₁-C₄, and n is 2 or 3.

2. A process for preparing the salt of diclofenac (2-[(2,6-dichlorophenyl)-amino]benzeneacetic acid) with a cyclic organic base having the general formula (I)



50 in which X is a group of the formula (CH₂)_m, in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group C₁-C₄, and n is 2 or 3, characterised by dissolving the diclofenac in a suitable organic solvent, adding said cyclic organic base, reacting said compounds together, removing the solvent and crystallising the product obtained.

3. A process as claimed in claim 2, characterised in that said solvent is acetone, ethanol or chloroform.


55 4. A process as claimed in claim 2, characterised in that the cyclic organic base (I) is added in equimolar quantity or in slight excess, with respect to the diclofenac.

5. A process as claimed in claim 2, characterised in that said reaction is conducted at ambient temperature under agitation for a time of between 0.5 and 3 hours.

6. A process as claimed in claim 2, characterised in that the solvent is removed by distillation under vacuum at a temperature of between 35 and 45°C.

7. A process as claimed in claim 2, characterised in that said crystallisation is implemented by treating the solvent removal residue with hexane or petroleum ether under energetic agitation.

8. Pharmaceutical compositions containing therapeutically active quantities of the salt of diclofenac with a cyclic organic base having the general formula (I)



15 in which X is a group of the formula $(\text{CH}_2)_m$, in which m is 0 or 1 or 2, or X is oxygen or S or NR, in which R is an alkyl group $\text{C}_1\text{--}/\text{C}_4$, and n is 2 or 3, together with pharmaceutically acceptable excipients.

9. Compositions as claimed in claim 8, characterised by containing a quantity of the salt of diclofenac with said cyclic organic base corresponding to 10-200 mg of diclofenac per unit dosage.

10. Compositions as claimed in claim 8, characterised by being prepared in granular form and packaged into water-impermeable sachets, to be dissolved in a little water to form a solutions for oral administration.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 87 11 6513

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	CHEMICAL ABSTRACTS, vol. 102, no. 26, 1st July 1985, page 336, abstract no. 225919f, Columbus, Ohio, US; A. FINI et al.: "Dissolution profiles of NSAID carboxylic acids and their salts with different counter ions", & PHARM. ACTA HELV. 1985, 60(2), 58-62 ---	1	C 07 C 101/447 C 07 D 295/08 A 61 K 31/195 A 61 K 31/40 A 61 K 31/445
A	WO-A-8 202 889 (CIBA-GEIGY AG) * Claims * -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 07 C 101/00 C 07 D 295/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 23-02-1988	Examiner PAUWELS G.R.A.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	